Every treatment plan is personalised. Dr Ashwin K.R. reviews your scans, pathology and, where relevant, biomarker results with a multidisciplinary team, then recommends a sequence of treatment that fits your cancer and your health.
Colon cancer is often curable, particularly when diagnosed at stages I to III, and some people with limited stage IV disease can achieve long-term remission when surgery is combined with systemic treatment.
Your outlook depends on three main factors:
| Stage | Treatment goal | What this typically means |
|---|---|---|
| Stage 0–I | Cure | Often treated successfully with surgery or endoscopic removal alone |
| Stage II | Cure | Surgery for most; chemotherapy added for some higher-risk cancers |
| Stage III | Cure | Surgery plus chemotherapy; many patients remain cancer-free long term |
| Stage IV – limited, removable spread | Long-term remission; cure possible for some | Systemic therapy plus surgery or ablation of metastases |
| Stage IV – widespread | Control, longer life, quality of life | Ongoing treatment; many patients live for several years |
Your colon cancer stage describes how deeply the tumour has grown into the bowel wall, whether it has reached nearby lymph nodes, and whether it has spread to distant organs — and it is one of the most important factors in planning your treatment.
| Stage | What it means | Typical treatment approach |
|---|---|---|
| Stage 0 (carcinoma in situ) | Abnormal cells only in the innermost lining of the colon | Removal during colonoscopy or local excision |
| Stage I | Grown into the inner layers of the bowel wall; no lymph nodes involved | Surgery (colectomy) alone |
| Stage II (IIA–IIC) | Grown through the bowel wall, possibly into nearby tissue; no lymph nodes involved | Surgery; chemotherapy considered for high-risk features |
| Stage III (IIIA–IIIC) | Spread to nearby lymph nodes, not distant organs | Surgery followed by adjuvant chemotherapy |
| Stage IV (IVA–IVC) | Spread to distant organs such as liver, lungs or peritoneum | Systemic therapy; surgery or ablation for selected patients |
According to US SEER registry data, about 9 in 10 people with localised colon cancer are alive five years after diagnosis, compared with the general population; survival is lower when the cancer has spread, and these averages cannot predict any one person's outcome.
| SEER stage group | What it includes | Approx. 5-year relative survival |
|---|---|---|
| Localised | Confined to the colon | About 90% |
| Regional | Spread to nearby tissues or lymph nodes | About 70–75% |
| Distant | Spread to distant organs (stage IV) | About 13–16% |
| All stages combined | — | About 63–65% |
Keep these points in mind when reading survival statistics:
Colorectal cancer is the umbrella term for cancers of the colon and rectum; colon cancer refers specifically to cancer in the first and longest part of the large intestine, and it is usually treated somewhat differently from rectal cancer.
| Feature | Colon cancer | Rectal cancer |
|---|---|---|
| Location | Caecum, ascending, transverse, descending and sigmoid colon | Last 12–15 cm of the large bowel |
| Main first treatment (non-metastatic) | Surgery (colectomy) | Often chemoradiation and/or chemotherapy before surgery |
| Role of radiation | Rarely used | Commonly used |
| Risk of permanent stoma | Low | Higher for very low tumours |
In most cases, colon cancer develops from a combination of ageing, genetics and lifestyle factors over many years, no single cause can be identified, and it is rarely the result of any one choice a person made.
Known risk factors include:
Your team will typically check for spread using a CT scan of the chest, abdomen and pelvis, blood tests including CEA, and examination of the lymph nodes removed during surgery.
Early colon cancer frequently causes no symptoms, which is why screening matters; when symptoms do appear, the most common are a change in bowel habits, blood in the stool and unexplained anaemia or tiredness.
| Symptom | What to notice | When to see a doctor |
|---|---|---|
| Change in bowel habits | Diarrhoea, constipation or narrower stools | If it lasts more than 3–4 weeks |
| Rectal bleeding | Bright red or very dark blood in or on the stool | Any unexplained bleeding |
| Iron-deficiency anaemia | Fatigue, breathlessness, pale skin | When found on a blood test or symptoms persist |
| Abdominal pain or bloating | Cramps or persistent fullness | If persistent or worsening |
| Incomplete emptying | Feeling the bowel has not emptied | If persistent |
| Unexplained weight loss | Loss of weight or appetite without trying | Promptly |
| Bowel obstruction | Severe pain, vomiting, no stool or gas | Emergency — seek care immediately |
The colon is wide and flexible, so a tumour can grow for some time before it bleeds noticeably, narrows the bowel or causes pain — having no early symptoms is common.
Many colon cancers are found through:
No — most rectal bleeding is caused by benign conditions such as haemorrhoids or anal fissures, but unexplained or persistent bleeding should be checked by a doctor, especially after age 40.
A standard colon cancer workup typically includes a complete colonoscopy with biopsy, a CT scan of the chest, abdomen and pelvis, blood tests including CEA, and molecular (biomarker) testing of the tumour.
| Test | Why it is done | When it is usually done |
|---|---|---|
| Colonoscopy with biopsy | Confirms diagnosis; checks the whole colon for other polyps or cancers | At diagnosis |
| CT chest, abdomen and pelvis | Checks for spread to liver, lungs or lymph nodes | Before treatment |
| CEA blood test | Baseline tumour marker for monitoring | Before surgery and during follow-up |
| Blood count, liver and kidney tests | Detects anaemia; checks fitness for treatment | Before surgery and each chemotherapy cycle |
| MMR / MSI testing | Guides immunotherapy and Lynch syndrome screening | On biopsy or surgical specimen — all patients |
| RAS, BRAF, HER2 testing | Guides targeted therapy | Mainly for stage IV |
| MRI liver or PET-CT | Clarifies uncertain findings; plans metastasis surgery | Selected patients |
CEA (carcinoembryonic antigen) is a protein that some colon cancers release into the blood; it is used to monitor treatment and detect possible recurrence, but it cannot diagnose colon cancer on its own.
Biomarkers are genetic features of your tumour that help predict which treatments are likely to work best, and biomarker testing is now a standard part of personalised colon cancer care.
| Biomarker | What it tells us | Treatment impact |
|---|---|---|
| dMMR / MSI-H | Tumour cannot repair DNA errors; about 15% of early and 4–5% of metastatic colon cancers | Often responds well to immunotherapy; may indicate Lynch syndrome; affects stage II chemotherapy decisions |
| KRAS / NRAS (RAS) mutation | Growth signal switched on | Anti-EGFR drugs are not effective; KRAS G12C has specific targeted options |
| BRAF V600E mutation | More aggressive subtype, often right-sided | Encorafenib plus an anti-EGFR antibody |
| HER2 amplification | Small percentage of RAS wild-type tumours | HER2-targeted combinations |
| NTRK / RET fusions (rare) | Uncommon gene fusions | Specific targeted drugs |
Seeking a second opinion is a reasonable, widely accepted step, and most oncologists welcome it — particularly for stage IV disease, rare tumour types or complex surgery.
| Bring this | Why it is needed |
|---|---|
| Pathology / biopsy report (and slides or blocks if requested) | Confirms diagnosis and tumour features |
| Scan images on disc plus radiology reports | Allows independent review of staging |
| Biomarker results (MSI/MMR, RAS, BRAF, HER2) | Determines eligibility for immunotherapy or targeted therapy |
| Operation notes and discharge summary | Explains what surgery was performed |
| Recent blood tests including CEA | Shows current status and trends |
| List of current medicines and allergies | Ensures safe treatment recommendations |
Colon cancer treatment is guided mainly by stage: early cancers are usually treated with surgery, stage III typically adds chemotherapy after surgery, and stage IV relies on systemic therapy, with surgery or local treatments for selected patients.
| Stage | Standard treatment | Additional options |
|---|---|---|
| 0 | Polypectomy or local excision | Surveillance colonoscopy |
| I | Colectomy with lymph node removal | Chemotherapy usually not needed |
| II | Colectomy | Adjuvant chemotherapy for high-risk features (e.g., T4, obstruction, perforation, fewer than 12 nodes); usually not for dMMR/MSI-H |
| III | Colectomy followed by chemotherapy (CAPOX or FOLFOX; fluoropyrimidine alone for some) | Clinical trials; ctDNA-guided approaches under study |
| IV – resectable | Chemotherapy plus surgery or ablation of liver/lung metastases | HAI pump, SBRT, cytoreductive surgery with HIPEC (selected cases) |
| IV – unresectable | Chemotherapy with targeted therapy or immunotherapy based on biomarkers | Maintenance and later-line therapy, palliative procedures, trials |
Surgery is the primary treatment with curative intent for colon cancer that has not spread, and it usually involves removing the affected section of colon together with its lymph nodes — an operation called a colectomy.
| Procedure | Part removed | Typical tumour location |
|---|---|---|
| Right hemicolectomy | Caecum, ascending colon, part of transverse colon | Right side |
| Extended right hemicolectomy | As above plus more transverse colon | Hepatic flexure / transverse colon |
| Left hemicolectomy | Descending colon | Left side |
| Sigmoid colectomy | Sigmoid colon | Sigmoid |
| Subtotal / total colectomy | Most or all of the colon | Multiple tumours, Lynch syndrome, FAP |
Laparoscopic (keyhole) and robotic colon surgery often offer, compared with open surgery:
The majority of people having surgery for colon cancer do not need a permanent colostomy, because the healthy ends of the bowel can usually be rejoined.
| Type of stoma | When it may be used | Usual duration |
|---|---|---|
| No stoma | Most planned colon cancer operations | — |
| Temporary colostomy or ileostomy | To protect a join while it heals, or after emergency surgery | Often reversed after about 3–6 months |
| Permanent colostomy | Uncommon in colon cancer; more often in very low rectal cancer | Long term |
Adjuvant chemotherapy is generally recommended for stage III colon cancer and considered for some high-risk stage II cancers, because clinical trials show it reduces the risk of the cancer returning.
| Regimen | Drugs | Typical duration | Schedule |
|---|---|---|---|
| CAPOX (XELOX) | Capecitabine tablets + oxaliplatin IV | 3 months (lower-risk stage III) or 3–6 months (higher-risk) | Every 3 weeks |
| FOLFOX | 5-FU + leucovorin + oxaliplatin IV | Usually 6 months | Every 2 weeks |
| Capecitabine alone | Tablets | 6 months | Every 3 weeks |
| 5-FU/leucovorin alone | IV infusion | 6 months | Varies by protocol |
Immunotherapy can be highly effective for colon cancers that are dMMR/MSI-H and is an approved first-line option for metastatic MSI-H colon cancer; for most microsatellite-stable (MSS) colon cancers, immunotherapy alone has shown limited benefit.
| Tumour type | Role of immunotherapy |
|---|---|
| Metastatic dMMR / MSI-H | Standard first-line option (e.g., pembrolizumab; nivolumab ± ipilimumab) |
| Early-stage dMMR / MSI-H | Pre-surgery immunotherapy showing strong results in clinical trials |
| MSS / pMMR (most colon cancers) | Mainly available through clinical trials |
Targeted therapies act on specific molecular features of a tumour and are used mainly alongside or after chemotherapy for stage IV colon cancer, with the choice guided by biomarker results.
| Target | Examples | Who may benefit |
|---|---|---|
| VEGF | Bevacizumab, ramucirumab, aflibercept, fruquintinib | Many patients with metastatic disease |
| EGFR | Cetuximab, panitumumab | RAS and BRAF wild-type tumours, especially left-sided |
| BRAF V600E | Encorafenib + cetuximab (± chemotherapy) | BRAF V600E-mutant tumours |
| KRAS G12C | Sotorasib or adagrasib with an anti-EGFR antibody | KRAS G12C-mutant tumours after prior therapy |
| HER2 | Trastuzumab-based combinations, trastuzumab deruxtecan, tucatinib | HER2-amplified, RAS wild-type tumours |
| Later-line | Trifluridine/tipiracil (± bevacizumab), regorafenib | Progression after earlier treatments |
Radiation therapy is used only occasionally in colon cancer, unlike rectal cancer, where it is a common part of treatment.
It may be considered for:
Colon cancer that has spread to the liver is often treatable, and when liver metastases can be completely removed, long-term survival is achievable for a meaningful proportion of patients.
| Treatment | How it works | Best suited for |
|---|---|---|
| Liver resection | Surgical removal of part of the liver | Metastases that can be completely removed |
| Pre-surgery chemotherapy | Shrinks tumours to make surgery possible | Borderline-removable disease |
| Ablation (microwave / radiofrequency) | Destroys tumours with heat | Small tumours, often under 3 cm |
| SBRT | Precisely targeted high-dose radiation | Patients unsuitable for surgery |
| HAI pump | Delivers chemotherapy directly to the liver | Selected patients at specialised centres |
| Radioembolisation (Y-90) | Radioactive beads delivered into liver arteries | Liver-dominant disease after other treatments |
Clinical trials offer access to promising new treatments under close supervision and are worth discussing at every stage of colon cancer, not only when other options have been used.
Current research areas include:
The most common side effects of colon cancer chemotherapy are fatigue, nausea, diarrhoea, low blood counts, nerve tingling (neuropathy) and, with capecitabine, sore hands and feet — and most can be reduced or managed with support from your team.
| Side effect | Most associated with | How it is managed |
|---|---|---|
| Peripheral neuropathy | Oxaliplatin | Dose reduction, shorter course, stopping oxaliplatin if severe |
| Cold sensitivity (hands, throat) | Oxaliplatin | Avoid cold drinks and cold air for a few days after each dose; wear gloves |
| Hand-foot syndrome | Capecitabine | Moisturisers, avoiding friction and heat, dose adjustment |
| Diarrhoea | 5-FU, capecitabine, irinotecan | Anti-diarrhoeal medicine and fluids; call your team if severe |
| Nausea and vomiting | Most regimens | Preventive anti-sickness medicines |
| Low blood counts / infection risk | Most regimens | Regular blood tests; urgent care for fever |
| Fatigue | All regimens | Pacing, gentle exercise, sleep and nutrition |
| Mouth sores | 5-FU, capecitabine | Mouth care, salt-water rinses, dose adjustment |
Significant hair loss is less common with the main colon cancer chemotherapy regimens; many people notice only mild thinning, although it varies by drug and person.
Many patients stay in hospital for about 3 to 7 days after colon surgery and return to most everyday activities within 4 to 6 weeks, with recovery often quicker after laparoscopic or robotic surgery.
| Time after surgery | What to expect | Activity guidance |
|---|---|---|
| Days 1–3 | Walking, fluids, light diet; pain controlled | Walk several times a day |
| Days 3–7 | Bowel function returns; discharge for most | Short walks; no lifting |
| Weeks 2–4 | Energy improving | Light household tasks; no heavy lifting |
| Weeks 4–6 | Most daily activities resume | Driving and desk work if cleared by surgeon |
| Weeks 6–12 | Near-normal routine | Strenuous exercise and heavy lifting as advised |
Many people continue working, fully or part-time, during colon cancer chemotherapy, although most need a period off after surgery.
There is no single colon cancer diet, but a balanced, protein-rich diet during treatment and a high-fibre, plant-forward diet in recovery can support healing and long-term health.
| Phase | Focus | Examples | Limit or avoid |
|---|---|---|---|
| First weeks after surgery | Soft, low-fibre, small frequent meals | Rice, curd, eggs, soups, well-cooked vegetables | Raw salads, whole nuts, very spicy food |
| During chemotherapy | Protein and fluids | Dal, eggs, fish, poultry, paneer, tofu | Unpasteurised foods; herbal supplements without advice |
| If diarrhoea | Binding foods, hydration | Rice, bananas, curd, oats, toast | Greasy, spicy, high-sugar foods |
| Long-term recovery | Fibre and plant foods | Vegetables, fruits, whole grains, legumes | Red and processed meat, sugary drinks, alcohol |
Regular physical activity after colon cancer treatment is associated with a lower risk of recurrence, and a large randomised trial (CHALLENGE, 2025) reported improved disease-free survival with a structured exercise programme.
Talk to your oncologist before starting aspirin or high-dose vitamin D; research is promising for some groups, but neither is a routine recommendation for everyone.
Stopping smoking and limiting alcohol are strongly advised: both are associated with better wound healing, fewer treatment complications and improved long-term outcomes after colon cancer.
The risk of colon cancer recurrence depends mainly on stage, and most recurrences that do occur are found within the first three years after treatment.
| Stage | Approximate risk of recurrence* |
|---|---|
| Stage I | Low — under about 10% |
| Stage II | Roughly 10–20%; higher with high-risk features |
| Stage III | Roughly 25–40%, depending on lymph node involvement and tumour depth |
*Estimates vary between studies and assume standard treatment. Your oncologist can give a personalised estimate.
After curative treatment, colon cancer follow-up typically includes regular clinic visits with CEA blood tests, periodic CT scans for the first few years, and scheduled colonoscopies.
| Test | Years 1–2 | Years 3–5 | After year 5 |
|---|---|---|---|
| Clinic visit + CEA | Every 3–6 months | Every 6 months | As advised |
| CT chest, abdomen, pelvis | Every 6–12 months | Every 6–12 months (stage II–III) | Not routine |
| Colonoscopy | At 1 year (or 3–6 months if incomplete before surgery) | At 3 years if prior result normal | Every 5 years |
Circulating tumour DNA (ctDNA) testing is a blood test that looks for tiny fragments of cancer DNA after surgery and can help identify patients at higher risk of recurrence.
Many colon cancer survivors return to work, family life, travel and exercise, and go on to live full, long lives after treatment.
Some people live with longer-term effects, which a survivorship care plan can address:
Most colon cancers are not inherited; an estimated 5–10% are linked to an inherited gene mutation, and having a close relative with colon cancer raises family members' risk.
| Hereditary syndrome | Key features |
|---|---|
| Lynch syndrome | Most common inherited cause; tumours usually dMMR/MSI-H; also raises endometrial, ovarian, stomach and urinary tract cancer risk |
| Familial adenomatous polyposis (FAP) | Hundreds to thousands of polyps, often from the teens; very high cancer risk without surgery |
| MUTYH-associated polyposis | Multiple polyps; inherited from both parents |
| Other rare syndromes | Peutz-Jeghers, juvenile polyposis |
Genetic counselling is recommended if:
Guidelines generally recommend that parents, siblings and children of a person with colon cancer begin screening colonoscopy at age 40, or 10 years before the relative's age at diagnosis, whichever is earlier.
| Who | When to start | How often |
|---|---|---|
| First-degree relative of a patient | Age 40, or 10 years before relative's diagnosis age | Colonoscopy about every 5 years |
| Lynch syndrome carrier | Age 20–30 depending on the gene | Colonoscopy every 1–2 years |
| FAP carrier / at-risk child | Around age 10–12 | Annual endoscopic screening |
| Average-risk adult | Age 45 in many guidelines (e.g., USPSTF) | Colonoscopy every 10 years or stool test per guidance |
Screening ages differ between countries; your doctor will advise on local recommendations.
Young-onset colorectal cancer (under age 50) is rising in many countries; the causes are still being researched, and factors such as obesity, diet, inactivity, gut microbiome changes and inherited syndromes are thought to contribute.
Colon cancer surgery seldom affects fertility directly, but chemotherapy can affect sperm and eggs, and fatigue, body-image changes or a stoma can affect intimacy — so it helps to raise these concerns before treatment starts.
| Option | Who it is for | Timing |
|---|---|---|
| Sperm banking | Men who may want children | Before chemotherapy begins |
| Egg or embryo freezing | Women who may want children | Before chemotherapy; takes about 2 weeks |
| Contraception | All patients of reproductive age | Throughout chemotherapy and as advised afterwards |
| Sexual health counselling | Anyone with concerns | Any time |
Feeling shocked, frightened, angry or low after a colon cancer diagnosis is a normal response, and emotional support is a core part of comprehensive cancer care.
The cost of colon cancer treatment varies widely with stage, type of surgery, chemotherapy regimen and the use of targeted or immunotherapy drugs, and many health insurance plans cover a substantial part of standard treatment.
Our patient financial counselling desk can help with:
Seek urgent medical care immediately if you develop a fever during chemotherapy or any of the symptoms below — they can signal serious but treatable complications.
| Symptom | Threshold | What to do |
|---|---|---|
| Fever during chemotherapy | 38°C (100.4°F) or higher, or chills | Go to emergency immediately |
| Diarrhoea | 4–6+ episodes a day above normal, or signs of dehydration | Call oncology team the same day |
| Abdominal pain / obstruction | Severe pain, swelling, vomiting, no stool or gas | Go to emergency immediately |
| Bleeding | Heavy rectal bleeding or black, tarry stools | Go to emergency immediately |
| Possible blood clot | Chest pain, breathlessness, or swollen, painful leg | Go to emergency immediately |
| Wound or stoma problem | Redness, discharge; stoma dark or not working | Call surgical team the same day |
| Unable to eat or drink | More than 24 hours | Call oncology team the same day |
Save your oncology helpline number: [24-hour helpline]
At [Hospital/Centre Name], every patient with colon cancer is reviewed by a multidisciplinary tumour board. We offer:
Book a consultation with our colon cancer specialists — [phone number] | [appointment link]
Medical disclaimer: This page provides general information and does not replace advice from your own doctor. Treatment decisions should be made with your oncology team based on your individual diagnosis. Statistics are approximate, drawn from published population data, and may not reflect individual outcomes.
Rectal cancer is often curable, particularly when diagnosed at stages I to III, and some people with limited stage IV disease can achieve long-term remission when systemic treatment is combined with surgery or other local therapies.
Your outlook depends mainly on:
| Stage | Treatment goal | What this typically means |
|---|---|---|
| Stage 0–I | Cure | Often treated with surgery alone, or local excision for selected early tumours |
| Stage II–III (locally advanced) | Cure, with bowel and sphincter preservation where possible | Chemotherapy and/or radiation before surgery; organ preservation for some complete responders |
| Stage IV – limited, removable spread | Long-term remission; cure possible for some | Systemic therapy plus treatment of the rectal tumour and metastases |
| Stage IV – widespread | Control, longer life, quality of life | Ongoing systemic therapy; local treatment for symptoms |
Rectal cancer arises in the last part of the large bowel, deep in the pelvis near the sphincter muscles, bladder and reproductive organs — so it is staged with MRI and is often treated with radiation and chemotherapy before surgery, unlike most colon cancers.
| Feature | Rectal cancer | Colon cancer |
|---|---|---|
| Location | Last 12–15 cm of the large bowel, above the anus | Caecum to sigmoid colon |
| Key staging scan | High-resolution pelvic MRI plus CT | CT chest, abdomen and pelvis |
| Treatment before surgery | Common for stage II–III (chemoradiation, TNT) | Uncommon |
| Role of radiation | Commonly used | Rarely used |
| Organ preservation (watch and wait) | An option for selected complete responders | Not standard |
| Risk of permanent stoma | Higher for very low tumours | Low |
| Local recurrence risk | Higher historically; reduced by TME surgery and pre-operative therapy | Lower |
Your rectal cancer stage describes how deeply the tumour has grown through the rectal wall, whether it has reached nearby lymph nodes, and whether it has spread to distant organs — and together with MRI risk features, it is one of the most important factors in planning treatment.
| Stage | What it means | Typical treatment approach |
|---|---|---|
| Stage 0 (carcinoma in situ) | Abnormal cells only in the inner lining | Local excision |
| Stage I (T1–T2, N0) | Grown into the inner layers or muscle of the rectal wall; no lymph nodes | TME surgery; local excision for selected T1 tumours |
| Stage II (T3–T4, N0) | Grown through the rectal wall, possibly into nearby tissue; no lymph nodes | Pre-operative therapy for most, then surgery or organ preservation |
| Stage III (any T, N1–N2) | Spread to nearby lymph nodes | Total neoadjuvant therapy, then surgery or organ preservation |
| Stage IV (M1) | Spread to distant organs such as liver or lungs | Systemic therapy; local treatment of rectum and metastases in selected patients |
Your pelvic MRI report describes how close the tumour is to key surgical boundaries and whether it has invaded nearby veins — features that help predict recurrence risk and decide whether you need treatment before surgery.
| MRI term | What it means | Why it matters |
|---|---|---|
| T stage (T1–T4) | Depth of tumour growth through the rectal wall | Deeper tumours usually need pre-operative therapy |
| N stage | Suspicious lymph nodes in the mesorectum | Node involvement raises recurrence risk |
| Mesorectal fascia (MRF) | Envelope of fatty tissue removed at surgery | Defines the planned surgical margin |
| CRM (circumferential resection margin) | Distance from tumour to the MRF; ≤1 mm is "threatened" or "involved" | A threatened CRM usually calls for pre-operative therapy |
| EMVI (extramural venous invasion) | Tumour growing into veins outside the rectal wall | Linked to higher risk of distant spread |
| Distance from anal verge | How far the tumour sits from the anal opening | Guides sphincter preservation and choice of surgery |
| Lateral pelvic nodes | Lymph nodes along the pelvic side walls | May change radiation or surgical plans |
Tumour height is one of the main factors in choosing treatment, because low rectal cancers sit close to the anal sphincter and are more challenging to remove while preserving normal bowel function.
| Location | Distance from anal verge | Key considerations |
|---|---|---|
| Low rectum | Up to about 5 cm | Sphincter preservation more complex; higher chance of permanent stoma; organ preservation often discussed |
| Mid rectum | About 5–10 cm | Sphincter-saving surgery usually possible; temporary stoma common |
| High rectum | About 10–15 cm | Sometimes treated more like colon cancer; radiation less often needed |
Definitions vary slightly between guidelines and centres.
According to US SEER registry data, about 9 in 10 people with localised rectal cancer are alive five years after diagnosis compared with the general population; survival is lower when cancer has spread, and these averages cannot predict any one person's outcome.
| SEER stage group | What it includes | Approx. 5-year relative survival |
|---|---|---|
| Localised | Confined to the rectum | About 90% |
| Regional | Spread to nearby tissues or lymph nodes | About 74% |
| Distant | Spread to distant organs (stage IV) | About 16–18% |
| All stages combined | — | About 67–68% |
Keep in mind when reading survival statistics:
In most cases, rectal cancer develops from a combination of ageing, genetics and lifestyle factors over many years; no single cause can be identified, and it is rarely the result of any one choice a person made.
Known risk factors include:
The most common symptoms of rectal cancer are rectal bleeding, a persistent change in bowel habits, and a feeling of needing to pass stool even when the bowel is empty — though early rectal cancer may cause no symptoms at all.
| Symptom | What to notice | When to see a doctor |
|---|---|---|
| Rectal bleeding | Blood on toilet paper, in or on the stool, or dark red blood | Any unexplained or persistent bleeding |
| Change in bowel habits | Diarrhoea, constipation, or more frequent stools | If it lasts more than 3–4 weeks |
| Tenesmus | Urge to pass stool even when the bowel is empty | If persistent |
| Narrow or ribbon-like stools | Stools thinner than usual | If persistent |
| Mucus in stool | Slimy discharge with or without stool | If persistent |
| Rectal or pelvic pain | Pain in the back passage or pelvis | Promptly |
| Anaemia or fatigue | Tiredness, breathlessness, pale skin | When found on a blood test or symptoms persist |
| Unexplained weight loss | Loss of weight or appetite without trying | Promptly |
Haemorrhoids (piles) and rectal cancer can both cause bleeding, so rectal cancer is sometimes initially mistaken for piles; persistent or unexplained rectal bleeding should be examined by a doctor.
Seek prompt assessment if bleeding:
| Feature | More typical of haemorrhoids | Warrants further investigation |
|---|---|---|
| Bleeding | Bright red, on paper, after straining | Mixed with stool, darker, or persistent |
| Bowel habits | Usually unchanged | New, persistent change |
| Other symptoms | Itching, a lump that comes and goes | Tenesmus, weight loss, anaemia, fatigue |
A standard rectal cancer workup typically includes colonoscopy with biopsy, a high-resolution pelvic MRI, a CT scan of the chest, abdomen and pelvis, a CEA blood test and biomarker testing — and together these determine whether treatment starts with surgery or with chemotherapy and radiation.
| Test | Why it is done | When it is usually done |
|---|---|---|
| Digital rectal examination | Assesses tumour position and relation to sphincter | At first consultation |
| Colonoscopy with biopsy | Confirms diagnosis; checks whole bowel for other polyps or cancers | At diagnosis |
| Rigid or flexible sigmoidoscopy | Measures exact distance from the anal verge | Before treatment planning |
| Pelvic MRI (rectal protocol) | Determines T and N stage, CRM, EMVI and tumour height | Before any treatment |
| CT chest, abdomen and pelvis | Checks for spread to liver, lungs or distant nodes | Before treatment |
| Endorectal ultrasound | Assesses very early tumours for local excision | Selected early cancers |
| CEA blood test | Baseline tumour marker for monitoring | Before treatment and during follow-up |
| MMR / MSI testing | Identifies dMMR tumours that may respond to immunotherapy; screens for Lynch syndrome | On biopsy — all patients |
| RAS, BRAF, HER2 testing | Guides targeted therapy | Mainly for stage IV |
| PET-CT | Clarifies uncertain findings | Selected patients |
If your rectal cancer is mismatch repair-deficient (dMMR/MSI-H), it may respond very well to immunotherapy, and for some patients this may reduce or avoid the need for radiation, chemotherapy or surgery.
Seeking a second opinion is a reasonable, widely accepted step, and it can be especially valuable in rectal cancer, where choices about sphincter preservation, radiation and organ preservation vary between centres.
| Bring this | Why it is needed |
|---|---|
| Biopsy report (and slides or blocks if requested) | Confirms diagnosis and tumour features |
| Pelvic MRI and CT images on disc plus reports | Allows independent review of staging and tumour height |
| Colonoscopy / sigmoidoscopy report | Confirms tumour distance from the anal verge |
| Biomarker results (MMR/MSI) | Determines eligibility for immunotherapy |
| Recent blood tests including CEA | Shows current status |
| List of medicines and allergies | Ensures safe recommendations |
Rectal cancer treatment is guided by stage, MRI risk features and tumour height: early cancers are usually treated with surgery alone, locally advanced cancers typically receive chemotherapy and/or radiation before surgery, and stage IV disease relies on systemic therapy with local treatment for selected patients.
| Stage / situation | Standard approach | Additional options |
|---|---|---|
| Stage 0 / early T1 | Local excision (TAMIS or TEM) | TME surgery if high-risk features on pathology |
| Stage I (T1–T2, N0) | TME surgery (low anterior resection or APR) | Chemoradiation with organ preservation in selected patients or trials |
| Stage II–III, lower risk | Pre-operative therapy then TME surgery; chemotherapy-first with selective radiation for some upper/mid tumours | Short-course radiation; organ preservation for complete responders |
| Stage II–III, higher risk (threatened CRM, EMVI, low tumour, N2) | Total neoadjuvant therapy (chemotherapy + chemoradiation or short-course radiation) then surgery | Watch and wait if complete clinical response |
| dMMR / MSI-H locally advanced | Immunotherapy (e.g., dostarlimab) — an emerging option at experienced centres | Surgery or chemoradiation if incomplete response |
| Stage IV | Systemic therapy with targeted or immunotherapy based on biomarkers | Surgery or ablation of metastases; pelvic radiation for symptoms |
| Recurrent rectal cancer | Individualised: re-irradiation, extended surgery (including pelvic exenteration) | Specialist centre referral |
Total neoadjuvant therapy (TNT) means giving all planned chemotherapy and radiation before surgery; for many patients with locally advanced rectal cancer it is now a widely recommended approach because it can shrink the tumour, treat hidden spread early and increase the chance of a complete response.
Potential benefits of TNT:
| Component | Typical regimen | Typical duration |
|---|---|---|
| Short-course radiation | 25 Gy in 5 daily fractions | 1 week |
| Long-course chemoradiation | About 50–54 Gy with capecitabine or 5-FU | 5–6 weeks, weekdays |
| Chemotherapy (before or after radiation) | FOLFOX or CAPOX (FOLFIRINOX in some protocols) | About 3–4 months |
| Response assessment | MRI, endoscopy and rectal examination | Several weeks after treatment ends |
Many people with rectal cancer do not need a permanent colostomy; sphincter-saving surgery is possible for a large proportion of patients, although a permanent stoma may be recommended when the tumour involves or sits very close to the anal sphincter.
| Type of stoma | When it may be used | Usual duration |
|---|---|---|
| Temporary loop ileostomy | Commonly after low anterior resection, to protect the new join while it heals | Often reversed after about 2–6 months (sometimes after chemotherapy) |
| Permanent end colostomy | After abdominoperineal resection (APR), when the sphincter must be removed | Lifelong |
| Elective permanent stoma | When bowel function after a very low join would likely be poor | Lifelong, by shared decision |
| No stoma | Organ preservation (watch and wait) or local excision | — |
The standard operation for rectal cancer is total mesorectal excision (TME), which removes the rectum with its surrounding fatty tissue and lymph nodes in one intact package — a technique associated with a substantially lower risk of the cancer returning in the pelvis.
| Procedure | What it involves | Typical use |
|---|---|---|
| Low anterior resection (LAR) with TME | Removes the tumour and mesorectum; bowel rejoined above the sphincter | Mid and upper rectal cancers; many low cancers |
| Ultra-low anterior resection / coloanal anastomosis | Bowel joined to or just above the anal canal | Low tumours where sphincters can be preserved |
| Intersphincteric resection | Removes part of the internal sphincter | Very low tumours in selected patients |
| Abdominoperineal resection (APR) | Removes rectum, anus and sphincters; permanent colostomy | Tumours involving the sphincter |
| Local excision (TAMIS / TEM) | Removes the tumour through the anus without abdominal surgery | Selected early T1 cancers or trial settings |
| Pelvic exenteration | Removes rectum with nearby involved organs | Locally advanced or recurrent cancer at specialist centres |
Surgical approaches:
"Watch and wait" (non-operative management) is an organ-preserving approach in which patients whose tumour appears to have disappeared completely after chemotherapy and radiation may avoid surgery and instead undergo intensive surveillance.
| Aspect | What to know |
|---|---|
| Who may be eligible | Patients with a complete clinical response confirmed by MRI, endoscopy and rectal examination |
| Evidence | In the OPRA trial, roughly half of patients receiving TNT preserved their rectum at three years; results vary by tumour and centre |
| Risk of regrowth | Roughly a quarter to a third of patients, most often within the first two years |
| If regrowth occurs | Many regrowths can be treated successfully with salvage surgery when found early |
| Commitment required | Frequent check-ups for at least five years, ideally at a centre experienced in organ preservation |
| Surveillance test | Years 1–2 | Years 3–5 |
|---|---|---|
| Digital rectal examination + endoscopy | Every 3–4 months | Every 6 months |
| Pelvic MRI | Every 3–6 months | Every 6–12 months |
| CEA blood test | Every 3–6 months | Every 6 months |
| CT chest, abdomen, pelvis | Every 6–12 months | Every 6–12 months |
Schedules vary between protocols; your team will set your exact plan.
Radiation therapy is commonly used for stage II and III rectal cancer to reduce the risk of pelvic recurrence and shrink the tumour before surgery, although some patients with favourable MRI features may be able to omit it after specialist review.
| Feature | Short-course radiation | Long-course chemoradiation |
|---|---|---|
| Dose | 25 Gy in 5 fractions | About 50–54 Gy in 25–28 fractions |
| Duration | 1 week | 5–6 weeks |
| Given with chemotherapy? | No (chemotherapy given separately) | Yes — capecitabine or 5-FU |
| Often preferred when | Convenience matters; combined with chemotherapy in TNT | Tumour shrinkage or organ preservation is a priority |
Chemotherapy is generally part of treatment for stage II–III and stage IV rectal cancer — given before surgery as part of TNT, alongside radiation to make it more effective, or after surgery depending on your plan.
| Use | Drugs | Purpose |
|---|---|---|
| With radiation | Capecitabine tablets or 5-FU infusion | Makes radiation more effective |
| TNT / adjuvant | FOLFOX or CAPOX | Treats microscopic spread; shrinks tumour |
| Intensified TNT (some protocols) | FOLFIRINOX | Higher response rates in fit patients |
| Metastatic disease | FOLFOX, FOLFIRI, CAPOX with targeted drugs | Controls cancer throughout the body |
Immunotherapy can be highly effective for dMMR/MSI-H rectal cancer and is increasingly used as first treatment in that group, while targeted therapies are used mainly for stage IV rectal cancer, chosen by biomarker results.
| Treatment | Examples | Who may benefit |
|---|---|---|
| Checkpoint immunotherapy | Dostarlimab, pembrolizumab, nivolumab ± ipilimumab | dMMR / MSI-H tumours |
| Anti-VEGF | Bevacizumab, aflibercept, ramucirumab, fruquintinib | Many patients with metastatic disease |
| Anti-EGFR | Cetuximab, panitumumab | RAS and BRAF wild-type metastatic tumours |
| BRAF V600E | Encorafenib + cetuximab | BRAF V600E-mutant tumours |
| KRAS G12C | Sotorasib or adagrasib with an anti-EGFR antibody | KRAS G12C-mutant tumours |
| HER2 | Trastuzumab-based combinations, trastuzumab deruxtecan | HER2-amplified tumours |
Rectal cancer that has spread to the liver or lungs is often treatable, and when metastases can be completely removed or ablated, long-term survival is achievable for a meaningful proportion of patients.
Clinical trials give access to promising new approaches under close supervision and are worth discussing at every stage of rectal cancer, particularly for organ preservation and dMMR tumours.
Active research areas include:
Radiation for rectal cancer commonly causes short-term bowel, bladder and skin irritation and fatigue, and can cause longer-term effects on bowel, sexual and reproductive function — short-term effects usually settle within weeks to a few months of finishing treatment.
| Timing | Possible side effects | How they are managed |
|---|---|---|
| During and shortly after | Diarrhoea, urgency, rectal discomfort | Diet changes, anti-diarrhoeal medicine, sitz baths |
| During and shortly after | Skin soreness around the anus and groin | Gentle skin care, barrier creams |
| During and shortly after | Frequent or burning urination | Fluids; urine tests to exclude infection |
| During and shortly after | Fatigue | Pacing, gentle activity, sleep |
| Longer term | Changes in bowel function | Diet, medicines, pelvic floor therapy |
| Longer term | Infertility; early menopause in women | Fertility preservation before treatment; hormone advice |
| Longer term | Erectile dysfunction or vaginal dryness/narrowing | Medicines, vaginal dilators, sexual health support |
| Longer term (uncommon) | Pelvic bone weakness (insufficiency fractures) | Bone health assessment; report new pelvic or hip pain |
Low anterior resection syndrome (LARS) is a group of bowel symptoms — frequency, urgency, clustering of stools and sometimes incontinence — that affects many people after sphincter-saving rectal surgery, and it often improves over one to two years with the right support.
| Approach | What it involves |
|---|---|
| Diet adjustments | Regular meals; adjusting fibre; identifying trigger foods |
| Medicines | Loperamide, bulking agents; other medicines as advised |
| Pelvic floor physiotherapy | Exercises and biofeedback to strengthen control |
| Transanal irrigation | Emptying the bowel on a schedule to reduce unpredictability |
| Sacral nerve stimulation | Implanted device for severe, persistent symptoms |
| Permanent stoma | Considered occasionally when symptoms remain severe despite treatment |
Rectal cancer treatment can affect sexual, urinary and reproductive function because the rectum lies close to the nerves and organs involved; nerve-sparing surgery reduces this risk, and fertility preservation should be discussed before treatment begins.
| Option | Who it is for | Timing |
|---|---|---|
| Sperm banking | Men who may want children | Before radiation or chemotherapy |
| Egg or embryo freezing | Women who may want children | Before treatment; takes about 2 weeks |
| Ovarian transposition | Selected women having pelvic radiation | Before radiation |
| Vaginal dilator programme | Women after pelvic radiation | Starting a few weeks after radiation |
| Erectile dysfunction treatment | Men with post-treatment difficulties | Any time after treatment |
| Sexual health counselling | Anyone with concerns | Any time |
Many patients stay in hospital for about 4 to 8 days after rectal cancer surgery and return to most everyday activities within 6 to 8 weeks, while bowel function can continue to adjust for up to one to two years.
| Time after surgery | What to expect | Activity guidance |
|---|---|---|
| Days 1–3 | Walking, fluids, light diet; stoma care teaching begins | Walk several times a day |
| Days 4–8 | Bowel or stoma function established; discharge for most | Short walks; no lifting |
| Weeks 2–4 | Energy improving; wound healing | Light household tasks; no heavy lifting |
| Weeks 6–8 | Most daily activities resume | Driving and desk work if cleared by surgeon |
| Months 2–6 | Stoma reversal for many with temporary ileostomy | Gradual return to exercise |
| Months 6–24 | Bowel function continues to settle after reversal | LARS support if needed |
The most common chemotherapy side effects in rectal cancer are fatigue, nausea, diarrhoea, low blood counts, nerve tingling from oxaliplatin and sore hands and feet from capecitabine — most can be reduced or managed with support from your team.
| Side effect | Most associated with | How it is managed |
|---|---|---|
| Tingling, numbness, cold sensitivity | Oxaliplatin | Avoid cold drinks and air for a few days after each dose; dose adjustment |
| Hand-foot syndrome | Capecitabine | Moisturisers, avoiding friction and heat; report early |
| Diarrhoea | Capecitabine, 5-FU, irinotecan | Anti-diarrhoeal medicine and fluids; call if severe |
| Nausea | Most regimens | Preventive anti-sickness medicines |
| Low blood counts / infection risk | Most regimens | Regular blood tests; urgent care for fever |
| Fatigue | All regimens | Pacing, gentle activity, sleep and nutrition |
There is no single rectal cancer diet, but adjusting what you eat during radiation, around surgery and with a stoma can reduce symptoms, while a balanced, high-fibre, plant-forward diet supports long-term health.
| Phase | Focus | Examples | Limit or avoid |
|---|---|---|---|
| During chemoradiation | Low-residue, gentle foods; fluids | Rice, curd, bananas, eggs, well-cooked vegetables | Very spicy, greasy or gas-forming foods |
| With a new ileostomy | Small frequent meals; salt and fluid replacement | White rice, potatoes, bananas, oral rehydration solution | Tough skins, nuts, popcorn, raw fibrous vegetables (blockage risk) |
| After stoma reversal | Regular meals; slow fibre reintroduction | Oats, soft fruits, soluble-fibre foods | Foods that trigger urgency (vary by person) |
| Long-term recovery | Fibre and plant foods | Vegetables, fruits, whole grains, legumes | Red and processed meat, sugary drinks, alcohol |
Many people adapt to a stoma within a few weeks to months, with training from a stoma nurse and the right appliances, and can return to work, travel, exercise and relationships.
| Feature | Ileostomy | Colostomy |
|---|---|---|
| Output | Liquid to porridge-like | Formed or semi-formed |
| Main concern | Dehydration and salt loss | Constipation or irregularity |
| Emptying | Often several times a day | Less often; usually more predictable |
| After rectal cancer surgery | Often temporary (loop ileostomy after LAR) | Often permanent (after APR) |
| Diet tips | Extra fluids and salt; chew well; oral rehydration if output is high | Regular meals, fibre and fluids |
Regular physical activity after colorectal cancer treatment is associated with better outcomes, and a large randomised trial (CHALLENGE, 2025) in colon cancer survivors reported improved disease-free survival with a structured exercise programme.
Stopping smoking and limiting alcohol are strongly advised: both are associated with better wound healing, fewer complications from surgery and radiation, and improved long-term outcomes.
The risk of rectal cancer recurrence depends mainly on stage, MRI risk features and response to treatment; with modern TME surgery and pre-operative therapy, local recurrence in the pelvis is now considerably less common than in the past, and most recurrences that do occur appear within the first three years.
| Type of recurrence | What it means | Approximate risk* |
|---|---|---|
| Local (pelvic) | Cancer returns near the original site | Often under 10% with modern treatment |
| Distant | Cancer appears in liver, lungs or elsewhere | Roughly 20–30% for locally advanced disease |
*Estimates vary between studies, stages and treatments. Your oncologist can give a personalised estimate.
After curative treatment, rectal cancer follow-up typically includes regular clinic visits with CEA tests, periodic CT scans, scheduled colonoscopies and, for some patients, examinations of the rectum or join.
| Test | Years 1–2 | Years 3–5 | After year 5 |
|---|---|---|---|
| Clinic visit + CEA | Every 3–6 months | Every 6 months | As advised |
| CT chest, abdomen, pelvis | Every 6–12 months | Every 6–12 months (stage II–III) | Not routine |
| Colonoscopy | At 1 year (or 3–6 months if incomplete before surgery) | At 3 years if prior result normal | Every 5 years |
| Proctoscopy / flexible sigmoidoscopy | Every 3–6 months after local excision | Every 6 months | As advised |
| Watch-and-wait surveillance | See watch-and-wait schedule above | See schedule above | As advised |
Circulating tumour DNA (ctDNA) testing is a blood test that looks for tiny fragments of cancer DNA and can help identify patients at higher risk of recurrence; its role in rectal cancer decisions is still being studied.
Many rectal cancer survivors return to work, family life, travel and exercise, and go on to live full, long lives, although some adapt to lasting changes in bowel, sexual or urinary function.
A survivorship care plan can address:
Most rectal cancers are not inherited; an estimated 5–10% of colorectal cancers are linked to an inherited gene mutation, and having a close relative with colorectal cancer raises family members' risk.
Genetic counselling is recommended if:
Guidelines generally recommend that parents, siblings and children of a person with colorectal cancer begin screening colonoscopy at age 40, or 10 years before the relative's age at diagnosis, whichever is earlier.
| Who | When to start | How often |
|---|---|---|
| First-degree relative of a patient | Age 40, or 10 years before relative's diagnosis age | Colonoscopy about every 5 years |
| Lynch syndrome carrier | Age 20–30 depending on the gene | Colonoscopy every 1–2 years |
| FAP carrier / at-risk child | Around age 10–12 | Annual endoscopic screening |
| Average-risk adult | Age 45 in many guidelines (e.g., USPSTF) | Colonoscopy every 10 years or stool test per guidance |
Screening ages differ between countries; your doctor will advise on local recommendations.
Young-onset colorectal cancer is rising in many countries, and rectal cancer accounts for a large share of these cases; the causes are still being researched, with obesity, diet, inactivity, gut microbiome changes and inherited syndromes thought to contribute.
Feeling shocked, frightened, embarrassed or low after a rectal cancer diagnosis is a normal response, and emotional support — including help with body image and intimacy — is a core part of comprehensive cancer care.
Many people continue working during parts of rectal cancer treatment, though time off is usually needed around surgery and sometimes during chemoradiation.
| Treatment phase | Typical work impact |
|---|---|
| Short-course radiation (1 week) | Brief disruption for daily visits |
| Long-course chemoradiation (5–6 weeks) | Daily visits; fatigue and bowel symptoms build over time |
| Chemotherapy cycles | Side effects often strongest in the first few days of each cycle |
| Surgery and recovery | Usually 6–8 weeks off, longer for physical jobs |
| Stoma reversal | Usually 2–4 weeks off |
The cost of rectal cancer treatment varies widely with stage, the type of radiation, surgery and drugs used, and whether a stoma is needed, and many health insurance plans cover a substantial part of standard treatment.
| Cost component | What it may include | What to ask |
|---|---|---|
| Diagnosis and staging | Colonoscopy, biopsy, pelvic MRI, CT, biomarker tests | Package or itemised pricing |
| Radiation therapy | Planning scans; short-course or long-course treatment | Number of sessions and technique used |
| Chemotherapy / immunotherapy / targeted therapy | Drugs, day-care, supportive medicines | Per-cycle cost; generic or biosimilar options |
| Surgery | Operation, hospital stay, robotic or laparoscopic charges | Package inclusions and exclusions |
| Stoma care | Bags, accessories, stoma nurse visits | Monthly supply cost and insurance coverage |
| Follow-up | Clinic visits, CEA, CT, colonoscopy, MRI | Estimated annual follow-up cost |
Our patient financial counselling desk can help with:
Seek urgent medical care immediately if you develop a fever during chemotherapy or any of the symptoms below — they can signal serious but treatable complications.
| Symptom | Threshold | What to do |
|---|---|---|
| Fever during chemotherapy | 38°C (100.4°F) or higher, or chills | Go to emergency immediately |
| Severe diarrhoea | 4–6+ episodes a day above normal, or dizziness | Call oncology team the same day |
| High ileostomy output | More than about 1.5–2 litres a day, or signs of dehydration | Call team the same day; go to emergency if dizzy or unable to drink |
| No stoma output | No output for 6+ hours with pain, bloating or vomiting | Go to emergency immediately |
| After surgery: fever or worsening abdominal pain | Especially in the first 2 weeks (possible leak) | Go to emergency immediately |
| Heavy rectal bleeding | Large amounts or clots | Go to emergency immediately |
| Unable to pass urine | Several hours with discomfort | Go to emergency immediately |
| Possible blood clot | Chest pain, breathlessness, or swollen, painful leg | Go to emergency immediately |
| Stoma colour change | Stoma turns dark, purple or black | Go to emergency immediately |
Save your oncology helpline number: [24-hour helpline]
At [Hospital/Centre Name], every patient with rectal cancer is reviewed by a dedicated multidisciplinary tumour board. We offer:
Book a consultation with our rectal cancer specialists — [phone number] | [appointment link]
Medical disclaimer: This page provides general information and does not replace advice from your own doctor. Treatment decisions should be made with your oncology team based on your individual diagnosis. Statistics are approximate, drawn from published population data, and may not reflect individual outcomes.
Medically reviewed by Dr Ashwin K.R. · Last reviewed: 10 October 2026
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.